{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:57Z","timestamp":1791245217328,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,3,24]],"date-time":"2019-03-24T00:00:00Z","timestamp":1553385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Octapharma"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Despite long\u2010standing safe and effective use of immunoglobulin replacement therapy (IgRT) in primary immunodeficiency, clinical data on IgRT in patients with secondary immunodeficiency (SID) due to B\u2010cell lymphoproliferative diseases are limited. Here, we examine the correlation between approved IgRT indications, treatment recommendations, and clinical practice in SID.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An international online survey of 230 physicians responsible for the diagnosis of SID and the prescription of IgRT in patients with hematological malignancies was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum immunoglobulin was measured in 83% of patients with multiple myeloma, 76% with chronic lymphocytic leukemia, and 69% with non\u2010Hodgkin lymphoma. Most physicians (85%) prescribed IgRT after \u22652 severe infections. In Italy, Germany, Spain, and the United States, immunoglobulin use was above average in patients with hypogammaglobulinemia, while in the UK considerably fewer patients received IgRT. The use of subcutaneous immunoglobulin was highest in France (34%) and lowest in Spain (19%). Immunologists measured specific antibody responses, performed test immunization, implemented IgRT, and used subcutaneous immunoglobulin more frequently than physicians overall.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The management of SID in hematological malignancies varied regionally. Clinical practice did not reflect treatment guidelines, highlighting the need for robust clinical studies on IgRT in this population and harmonization between countries and disciplines.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13223","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T01:46:25Z","timestamp":1551145585000},"page":"447-456","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies"],"prefix":"10.1111","volume":"102","author":[{"given":"Il\u2010Kang","family":"Na","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Tumor Immunology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health Berlin Germany"},{"name":"Experimental and Clinical Research Center Berlin Germany"},{"name":"Berlin Institute of Health Berlin Germany"},{"name":"Berlin\u2010Brandenburg Center for Regenerative Therapies Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Buckland","sequence":"additional","affiliation":[{"name":"UCL Centre for Immunodeficiency Royal Free Hospital and Great Ormond Street Hospital NHS Foundation Trusts London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Agostini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University Hospital, Padua University Treviso Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John David M.","family":"Edgar","sequence":"additional","affiliation":[{"name":"Regional Immunology Service The Royal Hospitals Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Friman","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Claude Bernard Lyon Lyon France"},{"name":"Service d'H\u00e9matologie Centre L\u00e9on B\u00e9rard Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"S\u00e1nchez\u2010Ram\u00f3n","sequence":"additional","affiliation":[{"name":"Departamento de Inmunolog\u00eda Cl\u00ednica, Hospital Cl\u00ednico San Carlos Universidad Complutense of Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Scheibenbogen","sequence":"additional","affiliation":[{"name":"Institute for Medical Immunology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t (FU) Berlin, Humboldt\u2010Universit\u00e4t zu Berlin and Berlin Institute of Health Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine Sapienza University of Rome Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12915"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.06.003"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldn034"},{"issue":"4","key":"e_1_2_8_6_1","first-page":"CD006501","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","author":"Raanani P","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12067"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-9995-5"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2086"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90180-5"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1208085"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00626"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05002.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810063191403"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902856824"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9720-1"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444700"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.101261"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2008.07.002"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12485"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12546"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2007.01.001"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12900"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0469-4"},{"key":"e_1_2_8_26_1","unstructured":"Octapharma Canada Inc.PANZYGA\u00ae product monograph.2017.https:\/\/www.octapharma.ca\/fileadmin\/user_upload\/octapharma.ca\/Product_Monographs\/PANZYGA-PM-EN.pdf. Accessed September 07 2018."},{"key":"e_1_2_8_27_1","unstructured":"Grifols Canada Ltd.FLEBOGAMMA\u00ae 10% product monograph.2017.https:\/\/pdf.hres.ca\/dpd_pm\/00040769.pdf. Accessed May 17 2018."},{"key":"e_1_2_8_28_1","unstructured":"CSL Behring Canada Inc.Privigen\u00ae product monograph.2018.http:\/\/labeling.cslbehring.ca\/PM\/CA\/Privigen\/EN\/Privigen-Product-Monograph.pdf. Accessed May 17 2018."},{"key":"e_1_2_8_29_1","unstructured":"European Medicines Agency.Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg).2012.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/12\/WC500136433.pdf. Accessed May 18 2018."},{"key":"e_1_2_8_30_1","unstructured":"European Medicines Agency.Guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration.2015.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/03\/WC500184870.pdf. Accessed May 14 2018."},{"key":"e_1_2_8_31_1","unstructured":"European Medicines Agency.Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg).2018.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2018\/07\/WC500252345.pdf. Accessed August 13 2018."},{"key":"e_1_2_8_32_1","unstructured":"Baxalta US Inc.GAMMAGARD S\/D full prescribing information.2017.https:\/\/www.fda.gov\/downloads\/BloodBloodProducts\/UCM197905.pdf. Accessed May 17 2018."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.09.023"},{"key":"e_1_2_8_34_1","unstructured":"Bundes\u00e4rztekammer.Querschnitts\u2010leitlinien (B\u00c4K) zur therapie mit blutkomponenten und plasmaderivaten.2014."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00317"},{"key":"e_1_2_8_36_1","unstructured":"Department of Health.Clinical guidelines for immunoglobulin use: update to second edition.2011.https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/216671\/dh_131107.pdf. Accessed May 17 2018."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08574.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13223","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13223","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13223","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:59:34Z","timestamp":1694343574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,24]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/ejh.13223"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13223","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,24]]},"assertion":[{"value":"2018-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}